2025
SJR Q2
JCR Q4 · 1,3
4 matched articles
SCIE
Journal detail
Journal of Vascular Research
- Publisher
- S. Karger AG
- Country
- Switzerland · Western Europe
- Type
- journal
- ISSN
-
1018117214230135
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,549
- Quartile Q2
- H-Index 85
- Cites/doc 1,27
- Docs (3y) 87
- Cites (3y) 167
Clarivate
Web of Science · JCR · 2025
- JCR Q Q4
- JIF 1,3
- 5Y JIF 1,7
- JCI 0,44
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Cardiology and Cardiovascular Medicine Q2
- Physiology Q3
Areas
- Biochemistry, Genetics and Molecular Biology
- Medicine
WoS categories
- Physiology | Peripheral Vascular Diseases
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q4 | 0,549 | 1,3 | 1,7 | 0,44 | Q3 | 85 |
| 2024 | Q2 | Q2 | 0,702 | 2,3 | 1,8 | 0,53 | Q3 | 83 |
| 2023 | Q3 | Q3 | 0,486 | 1,8 | 1,7 | 0,49 | Q3 | 83 |
| 2022 | Q3 | Q4 | 0,428 | 1,7 | 1,9 | 0,5 | Q3 | 83 |
| 2021 | Q3 | Q4 | 0,422 | 2 | 2,2 | 0,48 | Q3 | 83 |
| 2020 | Q2 | Q4 | 0,58 | 1,9 | 2,4 | 0,52 | Q3 | 83 |
| 2019 | Q2 | Q3 | 0,596 | 1,7 | 2 | 0,48 | Q3 | 83 |
| 2018 | — | Q3 | — | 1,9 | 2,6 | 0,54 | Q3 | — |
| 2017 | Q1 | Q3 | 1,129 | 2 | 2,6 | 0,46 | Q3 | 83 |
| 2016 | Q2 | Q3 | 1,037 | 1,8 | 2,3 | — | — | 83 |
| 2015 | Q1 | Q3 | 1,14 | 2,2 | 2,5 | — | — | 83 |
| 2014 | Q1 | Q2 | 1,301 | 2,9 | 2,7 | — | — | 83 |
| 2013 | Q1 | Q2 | 1,11 | 2,4 | 2,3 | — | — | 83 |
| 2012 | Q1 | Q2 | 1,035 | 2,4 | 2,4 | — | — | 83 |
| 2011 | Q1 | Q2 | 1,008 | 2,7 | 2,3 | — | — | 83 |
| 2010 | Q1 | Q2 | 1,086 | 2,8 | 2,5 | — | — | 83 |
| 2009 | — | Q2 | — | 2,9 | 2,6 | — | — | — |
| 2008 | — | Q2 | — | 2,8 | 2,7 | — | — | — |
| 2007 | — | Q2 | — | 2,5 | 2,6 | — | — | — |
| 2006 | — | Q2 | — | 2,5 | — | — | — | — |
| 2005 | — | Q2 | — | 2,8 | — | — | — | — |
| 2004 | — | Q2 | — | 2,5 | — | — | — | — |
| 2003 | — | Q2 | — | 2,6 | — | — | — | — |
| 2002 | — | Q2 | — | 2,5 | — | — | — | — |
| 2001 | — | Q2 | — | 1,9 | — | — | — | — |
| 2000 | — | Q1 | — | 2,7 | — | — | — | — |
| 1999 | — | Q1 | — | 3,6 | — | — | — | — |
| 1998 | — | Q1 | — | 2,7 | — | — | — | — |
| 1997 | — | Q1 | — | 2,5 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | Q3 | 76/100 |
| 2025 | PHYSIOLOGY | SCIE | Q4 | Q4 | 81/89 |
| 2024 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q3 | 48/98 |
| 2024 | PHYSIOLOGY | SCIE | Q2 | Q4 | 42/87 |
| 2023 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 62/96 |
| 2023 | PHYSIOLOGY | SCIE | Q3 | Q4 | 62/85 |
| 2022 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | Q3 | 56/68 |
| 2022 | PHYSIOLOGY | SCIE | Q4 | Q4 | 67/79 |
| 2021 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | Q3 | 55/67 |
| 2021 | PHYSIOLOGY | SCIE | Q4 | Q4 | 69/81 |
| 2020 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | Q3 | 55/65 |
| 2020 | PHYSIOLOGY | SCIE | Q4 | Q4 | 65/81 |
| 2019 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | Q3 | 53/65 |
| 2019 | PHYSIOLOGY | SCIE | Q3 | Q4 | 60/81 |
| 2018 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 46/65 |
| 2018 | PHYSIOLOGY | SCIE | Q3 | Q4 | 57/81 |
| 2017 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 43/65 |
| 2017 | PHYSIOLOGY | SCIE | Q3 | Q4 | 54/83 |
| 2016 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 46/63 |
| 2016 | PHYSIOLOGY | SCIE | Q3 | — | 57/84 |
| 2015 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 41/63 |
| 2015 | PHYSIOLOGY | SCIE | Q3 | — | 42/83 |
| 2014 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 24/60 |
| 2014 | PHYSIOLOGY | SCIE | Q2 | — | 28/83 |
| 2013 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 32/65 |
| 2013 | PHYSIOLOGY | SCIE | Q2 | — | 36/81 |
| 2012 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 34/68 |
| 2012 | PHYSIOLOGY | SCIE | Q2 | — | 36/80 |
| 2011 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 27/68 |
| 2011 | PHYSIOLOGY | SCIE | Q2 | — | 29/79 |
| 2010 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 24/68 |
| 2010 | PHYSIOLOGY | SCIE | Q2 | — | 31/78 |
| 2009 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 23/61 |
| 2009 | PHYSIOLOGY | SCIE | Q2 | — | 31/75 |
| 2008 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 23/56 |
| 2008 | PHYSIOLOGY | SCIE | Q2 | — | 29/74 |
| 2007 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 23/54 |
| 2007 | PHYSIOLOGY | SCIE | Q2 | — | 32/78 |
| 2006 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 21/52 |
| 2006 | PHYSIOLOGY | SCIE | Q2 | — | 30/78 |
| 2005 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 18/51 |
| 2005 | PHYSIOLOGY | SCIE | Q2 | — | 27/75 |
| 2004 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 19/51 |
| 2004 | PHYSIOLOGY | SCIE | Q2 | — | 25/74 |
| 2003 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 17/52 |
| 2003 | PHYSIOLOGY | SCIE | Q2 | — | 22/74 |
| 2002 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 18/52 |
| 2002 | PHYSIOLOGY | SCIE | Q2 | — | 25/73 |
| 2001 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 21/50 |
| 2001 | PHYSIOLOGY | SCIE | Q2 | — | 27/74 |
| 2000 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 15/45 |
| 2000 | PHYSIOLOGY | SCIE | Q1 | — | 19/76 |
| 1999 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | — | 9/44 |
| 1999 | PHYSIOLOGY | SCIE | Q1 | — | 9/74 |
| 1998 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 12/39 |
| 1998 | PHYSIOLOGY | SCIE | Q1 | — | 11/67 |
| 1997 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 12/38 |
| 1997 | PHYSIOLOGY | SCIE | Q1 | — | 15/65 |